"A novel in vivo model for the study of human breast cancer metastasis using primary breast tumor-initiating cells from patient biopsies"

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Marsden, Carolyn G ^a   Wright, Mary J ^b   Carrier, Latonya ^a   Moroz, Krzysztof ^b   Pochampally, Radhika ^a   Rowan, Brian G ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dormancy; Emt; Metastasis; Primary breast tumor initiating cells

Indexed keywords

BETA CATENIN; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; FIBRONECTIN; PROGESTERONE RECEPTOR; UVOMORULIN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER GRADING; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; INTRADUCTAL CARCINOMA; METASTASIS; MORPHOLOGY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; ANIMAL; BIOPSY; BREAST; DISEASE MODEL; EXPERIMENTAL NEOPLASM; METABOLISM; NUDE MOUSE; PAGET NIPPLE DISEASE; PATHOLOGY;

ANIMALS; BIOPSY; BREAST; CARCINOMA, DUCTAL, BREAST; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; TUMOR MARKERS, BIOLOGICAL;

EID: 84855490610     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-10     Document Type: Article

References (55)

1. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell 2009, 139(7):1315-1326. 10.1016/j.cell.2009.11.025, 2810531, 20064377.
2. Allan AL, Vantyghem SA, Tuck AB, Chambers AF. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis 2006, 26:87-98.
3. Giovanella BC, Vardeman DM, Williams LJ, Taylor DJ, De Ipolyi PD, Greeff PJ, et al. Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene. Int J Cancer 1991, 47(1):66-71. 10.1002/ijc.2910470113, 1985881.
4. Mattern J, Bak M, Hahn EW, Volm M. Human tumor xenografts as model for drug testing. Cancer Metastasis Rev 1988, 7(3):263-284. 10.1007/BF00047755, 3067903.
5. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de CP. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007, 13(13):3989-3998. 10.1158/1078-0432.CCR-07-0078, 17606733.
6. Al Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(7):3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
7. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006, 66(19):9339-9344. 10.1158/0008-5472.CAN-06-3126, 16990346.
8. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007, 58:267-284. 10.1146/annurev.med.58.062105.204854, 17002552.
9. Wicha MS. Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res 2006, 12(19):5606-5607. 10.1158/1078-0432.CCR-06-1537, 17020960.
10. Al Hajj M. Cancer stem cells and oncology therapeutics. Curr Opin Oncol 2007, 19(1):61-64.
11. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res 2006, 66(4):1883-1890. 10.1158/0008-5472.CAN-05-3153, 16488983.
12. Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 2006, 312(19):3701-3710. 10.1016/j.yexcr.2006.08.030, 17046749.
13. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131(6):1109-1123. 10.1016/j.cell.2007.10.054, 18083101.
14. Li HZ, Yi TB, Wu ZY. Suspension culture combined with chemotherapeutic agents for sorting of breast cancer stem cells. BMC Cancer 2008, 8:135. 10.1186/1471-2407-8-135, 2390573, 18477410.
15. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98(24):1777-1785. %20, 10.1093/jnci/djj495, 17179479.
16. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005, 65(13):5506-5511. 10.1158/0008-5472.CAN-05-0626, 15994920.
17. Li F, Tiede B, Massague J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007, 17(1):3-14. 10.1038/sj.cr.7310118, 17179981.
18. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9(4):274-284. 10.1038/nrc2622, 19308067.
19. Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, Rodrigues M, Dieras V, Mignot L, et al. Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse. Clin Exp Metastasis 2008, 25(8):871-875. 10.1007/s10585-008-9203-1, 18989740.
20. Fidler IJ. The organ microenvironment and cancer metastasis. Differentiation 2002, 70(9-10):498-505. 10.1046/j.1432-0436.2002.700904.x, 12492492.
21. Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 2010, 46(7):1181-1188. 10.1016/j.ejca.2010.02.027, 2856784, 20304630.
22. Marsden CG, Wright MJ, Pochampally R, Rowan BG. Breast tumor-initiating cells isolated from patient core biopsies for study of hormone action. Methods Mol Biol 2009, 590:363-375. 10.1007/978-1-60327-378-7_23, 19763516.
23. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003, 17(10):1253-1270. 10.1101/gad.1061803, 196056, 12756227.
24. Becker M, Nitsche A, Neumann C, Aumann J, Junghahn I, Fichtner I. Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems. Br J Cancer 2002, 87(11):1328-1335. 10.1038/sj.bjc.6600573, 2408903, 12439725.
25. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993, 85(3):200-206. 10.1093/jnci/85.3.200, 8423624.
26. Maitra A, Ashfaq R, Gunn CR, Rahman A, Yeo CJ, Sohn TA, et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 2002, 118(2):194-201. 10.1309/TPG4-CK1C-9V8V-8AWC, 12162677.
27. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(7):3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
28. Prochazka M, Gaskins HR, Shultz LD, Leiter EH. The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proc Natl Acad Sci USA 1992, 89(8):3290-3294. 10.1073/pnas.89.8.3290, 48852, 1373493.
29. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009, 28(1-2):151-166. 10.1007/s10555-008-9179-y, 19153669.
30. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 2007, 213(2):374-383. 10.1002/jcp.21223, 17680632.
31. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69(4):1302-1313. 10.1158/0008-5472.CAN-08-2741, 2819227, 19190339.
32. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 2009, 7(6):e1000121. 10.1371/journal.pbio.1000121, 2683567, 19492080.
33. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008, 10(2):R25. 10.1186/bcr1982, 2397524, 18366788.
34. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 2000, 97(26):14720-14725. 10.1073/pnas.97.26.14720, 18985, 11121071.
35. Klein SM, Behrstock S, McHugh J, Hoffmann K, Wallace K, Suzuki M, et al. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther 2005, 16(4):509-521. 10.1089/hum.2005.16.509, 15871682.
36. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003, 5(6):R217-R222. 10.1186/bcr651, 314411, 14580257.
37. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/. Breast Cancer Res 2008, 10(1):R10. 10.1186/bcr1855, 2374965, 18241344.
38. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1(5):555-567. 10.1016/j.stem.2007.08.014, 2423808, 18371393.
39. Donnenberg VS, Donnenberg AD, Zimmerlin L, Landreneau RJ, Bhargava R, Wetzel RA, et al. Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. Cytometry B Clin Cytom 2010, 78(5):287-301.
40. Raouf A, Zhao Y, To K, Stingl J, Delaney A, Barbara M, et al. Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell 2008, 3(1):109-118. 10.1016/j.stem.2008.05.018, 18593563.
41. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004, 22(22):4514-4522. 10.1200/JCO.2004.10.125, 15542802.
42. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006, 5(16):1779-1787. 10.4161/cc.5.16.3018, 16931911.
43. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006, 98(5):316-325. 10.1093/jnci/djj068, 16507828.
44. Agiostratidou G, Hulit J, Phillips GR, Hazan RB. Differential cadherin expression: potential markers for epithelial to mesenchymal transformation during tumor progression. J Mammary Gland Biol Neoplasia 2007, 12(2-3):127-133. 10.1007/s10911-007-9044-6, 17564818.
45. Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007, 13(6):1663-1674. 10.1158/1078-0432.CCR-06-2854, 17363519.
46. Goldstein RH, Weinberg RA, Rosenblatt M. Of mice and (wo)men: mouse models of breast cancer metastasis to bone. J Bone Miner Res 2010, 25(3):431-436. 10.1002/jbmr.68, 20200984.
47. Valentiner U, Brooks SA, Schumacher U. In vivo xenograft models of breast cancer metastasis. Methods Mol Med 2006, 120:479-488.
48. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9(4):265-273. 10.1038/nrc2620, 19262571.
49. Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 2010, 9:179. 10.1186/1476-4598-9-179, 2907333, 20609236.
50. Yates C, Shepard CR, Papworth G, Dash A, Beer SD, Tannenbaum S, et al. Novel three-dimensional organotypic liver bioreactor to directly visualize early events in metastatic progression. Adv Cancer Res 2007, 97:225-246.
51. Yates CC, Shepard CR, Stolz DB, Wells A. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer 2007, 96(8):1246-1252. 10.1038/sj.bjc.6603700, 2360137, 17406365.
52. Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, Hoenorhoff MJ, et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 2008, 68(15):6241-6250. 10.1158/0008-5472.CAN-07-6849, 2561279, 18676848.
53. Allgayer H, Aguirre-Ghiso JA. The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?. APMIS 2008, 116(7-8):602-614. 10.1111/j.1600-0463.2008.00997.x, 2821075, 18834405.
54. Fehm T, Krawczyk N, Solomayer EF, Becker-Pergola G, Durr-Storzer S, Neubauer H, et al. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 2008, 10(5):R76. 10.1186/bcr2143, 2614509, 18793387.
55. Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009, 11(4):R59. 10.1186/bcr2349, 2750121, 19664291.